Skip to content

Insider · CIK 0001854968

Amy DuRoss

director

Files at BLFS (BIOLIFE SOLUTIONS INC). First filing Mar 20, 2025, latest Dec 17, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $446k sold

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
37Weak
BLFSsell 6
BIOLIFE SOLUTIONS INC
$49k
2,000 shares
-10%-
45Moderate
BLFSsell 8
BIOLIFE SOLUTIONS INC
$108k
4,000 shares
-16%-
46Moderate
BLFSsell 8
BIOLIFE SOLUTIONS INC
$149k
6,000 shares
-20%-
26Weak
BLFSsell 710b5-1
BIOLIFE SOLUTIONS INC
$141k
5,632 shares
-19%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Oct 6, 2026BLFS
BIOLIFE SOLUTIONS INC
DDisposition to issuer
Common Stock
-26,857--04 d ago
Feb 24, 2026BLFS
BIOLIFE SOLUTIONS INC
AGrant or award
Common Stock
+8,170--26,857Feb 26, 2026
Dec 15, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-2,000$24.60$49k18,687Dec 17, 2025
Nov 25, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-2,000$27.00$54k22,687Nov 28, 2025
Nov 26, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-2,000$27.00$54k20,687Nov 28, 2025
Nov 19, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-477$24.50$12k30,210Nov 21, 2025
Nov 20, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-4,523$24.51$111k25,687Nov 21, 2025
Nov 21, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock
-1,000$26.00$26k24,687Nov 21, 2025
Mar 14, 2025BLFS
BIOLIFE SOLUTIONS INC
SOpen-market sale
Common Stock10b5-1
-5,632$24.96$141k23,811Mar 20, 2025
Mar 18, 2025BLFS
BIOLIFE SOLUTIONS INC
AGrant or award
Common Stock10b5-1
+6,876--30,687Mar 20, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Amy DuRoss: insider trades and track record | InsiderTell